Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro AMol Pharmacol 2007[Jun]; 71 (6): 1445-56The advent of the highly selective cannabinoid receptor (CB1) antagonist, rimonabant (SR141716; Acomplia) can revolutionize the ability of the clinicians to manage obesity. Large-scale clinical trials have demonstrated that rimonabant therapy can reduce obesity. Although, the precise mechanisms of action of rimonabant have to be further dissected, it is emerging, from both preclinical and clinical research, that not only is rimonabant an antiobesity drug, but also its pleiotropic functions affect a broad range of diseases, from obesity-related comorbidities to drug dependence and cancer. Here we review recent data from the literature and discuss the full pharmacological potential of this drug.|Anti-Obesity Agents/*therapeutic use[MESH]|Antineoplastic Agents/pharmacology[MESH]|Body Weight/*drug effects[MESH]|Humans[MESH]|Neurodegenerative Diseases/drug therapy[MESH]|Obesity/*drug therapy[MESH]|Piperidines/*therapeutic use[MESH]|Pyrazoles/*therapeutic use[MESH]|Receptor, Cannabinoid, CB1/antagonists & inhibitors[MESH]|Rimonabant[MESH]|Smoking Cessation[MESH]|Substance-Related Disorders/etiology[MESH] |
